https://www.clinicaltrials.gov/ct2/show/NCT02962895
Safety and Efficacy of VAY736 in Patients With Primary Sjogren’s Syndrome (pSS)
Brief Summary:
This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters
Condition or disease Intervention/treatment Phase
Primary Sjogren Syndrome
Biological: VAY736
Other: Placebo
Phase 2
Study Design
Go to sections
Study Type : Interventional (Clinical Trial)
Actual Enrollment : 195 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren’s Syndrome (pSS)
Actual Study Start Date : June 27, 2017
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : June 30, 2020
